|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 16478 |
FusionGeneSummary for HMGN2P46_ST14 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: HMGN2P46_ST14 | Fusion gene ID: 16478 | Hgene | Tgene | Gene symbol | HMGN2P46 | ST14 | Gene ID | 283651 | 6768 |
| Gene name | high mobility group nucleosomal binding domain 2 pseudogene 46 | suppression of tumorigenicity 14 | |
| Synonyms | C15orf21|D-PCa-2 | ARCI11|HAI|MT-SP1|MTSP1|PRSS14|SNC19|TADG15|TMPRSS14 | |
| Cytomap | 15q21.1 | 11q24.3 | |
| Type of gene | pseudo | protein-coding | |
| Description | Dresden prostate cancer 2Dresden prostate carcinoma 2 | suppressor of tumorigenicity 14 proteinmembrane-type serine protease 1prostaminserine protease 14serine protease TADG-15suppression of tumorigenicity 14 (colon carcinoma)suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin)tumor a | |
| Modification date | 20180519 | 20180523 | |
| UniProtAcc | Q9Y5Y6 | ||
| Ensembl transtripts involved in fusion gene | ENST00000409454, | ENST00000278742, | |
| Fusion gene scores | * DoF score | 6 X 4 X 1=24 | 4 X 3 X 3=36 |
| # samples | 5 | 4 | |
| ** MAII score | log2(5/24*10)=1.05889368905357 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: HMGN2P46 [Title/Abstract] AND ST14 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | ST14 | GO:0006508 | proteolysis | 19911255 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | PRAD | TCGA-H9-7775-01A | HMGN2P46 | chr15 | 45806161 | + | ST14 | chr11 | 130058009 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 3UTR-3CDS | ENST00000409454 | ENST00000278742 | HMGN2P46 | chr15 | 45806161 | + | ST14 | chr11 | 130058009 | + |
Top |
FusionProtFeatures for HMGN2P46_ST14 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| HMGN2P46 | ST14 |
| Lectin that binds to various sugars: galactose > mannose= fucose > N-acetylglucosamine > N-acetylgalactosamine(PubMed:10224141). Acts as a chemoattractant, probably involved inthe regulation of cell migration (PubMed:28301481).{ECO:0000269|PubMed:10224141, ECO:0000269|PubMed:28301481}. | Degrades extracellular matrix. Proposed to play a rolein breast cancer invasion and metastasis. Exhibits trypsin-likeactivity as defined by cleavage of synthetic substrates with Argor Lys as the P1 site. Involved in the terminal differentiation ofkeratinocytes through prostasin (PRSS8) activation and filaggrin(FLG) processing. {ECO:0000269|PubMed:18843291}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for HMGN2P46_ST14 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for HMGN2P46_ST14 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| HMGN2P46 | ELAVL1 | ST14 | SPINT1, PDGFC, RGS16, AKT1, APC, CASP8, CDKN2C, CHEK2, NOTCH2, PHB, RAD51, STK11, TGFB1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for HMGN2P46_ST14 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Tgene | ST14 | Q9Y5Y6 | DB00013 | Urokinase | Suppressor of tumorigenicity 14 protein | biotech | approved|investigational|withdrawn |
Top |
RelatedDiseases for HMGN2P46_ST14 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Tgene | ST14 | C1835851 | Ichthyosis with hypotrichosis, autosomal recessive | 2 | CTD_human;ORPHANET;UNIPROT |
| Tgene | ST14 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | ST14 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Tgene | ST14 | C0265962 | Ichthyosis linearis circumflexa | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|